9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $27M | -$27M | 0.0% | -96.7% | -$22M | — | $27M |
| 2024 | $9M | -$41M | 0.0% | -446.9% | -$36M | $37000 | $22M |
| 2023 | $5M | -$51M | 0.0% | -949.9% | -$40M | $4M | $49M |
| 2022 | $1M | -$53M | 0.0% | -4275.1% | -$42M | $8M | $52M |
| 2021 | $15M | -$44M | 0.0% | -292.6% | -$40M | $0 | $64M |
| 2020 | $3M | -$45M | 0.0% | -1428.0% | -$33M | — | $75M |
| 2019 | $3M | -$37M | 0.0% | -1063.2% | -$31M | — | $44M |
| 2018 | $1M | -$39M | 0.0% | -3386.7% | -$28M | — | $21M |
| 2017 | — | -$23M | — | — | -$13M | — | $64M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $6M | -$5M | 0.0% | -94.1% | -$11M | — | $16M |
| Dec '25 | $22M | $2M | 0.0% | 9.0% | -$1M | — | $27M |
| Sep '25 | $2M | -$7M | 0.0% | -353.4% | -$9M | — | $12M |
| Jun '25 | $3M | -$8M | 0.0% | -292.3% | -$3M | — | $27M |
| Mar '25 | $421000 | -$12M | 0.0% | -2921.4% | -$8M | — | $13M |
| Dec '24 | $2M | -$9M | 0.0% | -611.2% | -$9M | $37000 | $22M |
| Sep '24 | $3M | -$9M | 0.0% | -264.2% | -$8M | $1M | $32M |
| Jun '24 | $3M | -$10M | 0.0% | -390.6% | -$10M | $2M | $30M |
| Mar '24 | $2M | -$12M | 0.0% | -737.8% | -$10M | $3M | $41M |
| Dec '23 | $2M | -$13M | 0.0% | -759.6% | -$11M | $4M | $49M |
| Sep '23 | $2M | -$11M | 0.0% | -543.8% | -$8M | $5M | $55M |
| Jun '23 | $1M | -$13M | 0.0% | -978.1% | -$10M | $6M | $53M |
| Mar '23 | $187000 | -$13M | 0.0% | -7155.1% | -$11M | $7M | $56M |
| Dec '22 | $151000 | -$15M | 0.0% | -9845.0% | -$11M | $8M | $52M |
| Sep '22 | $68000 | -$11M | 0.0% | -16222.1% | -$7M | $9M | $30M |
| Jun '22 | $26000 | -$13M | 0.0% | -50346.2% | -$13M | $10M | $66M |
| Mar '22 | $1M | -$14M | 0.0% | -1423.8% | -$12M | $10M | $68M |
| Dec '21 | $8M | -$8M | 0.0% | -95.6% | -$11M | $0 | $64M |
| Sep '21 | $2M | -$13M | 0.0% | -543.5% | -$7M | — | $68M |
| Jun '21 | $3M | -$10M | 0.0% | -376.2% | -$10M | — | $74M |
How the market has priced CUE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cue Biopharma, Inc.'s revenue has grown 54.2% per year. These are computed facts, not advice.
As of FY2025, Cue Biopharma, Inc. reported — of total debt against $27M of cash; operating income covered interest expense -265.5×.
In FY2025, gross margin was —, operating margin -96.7%, and net margin -96.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.